Background. The directed study of the functional proteome in colorectal cancer (CRC) has identified critical protein markers and signaling pathways; however, the prognostic relevance of many of these proteins remains unclear. Methods. We determined the prognostic implications of the functional proteome in 263 CRC tumor samples from patients treated at MD Anderson Cancer Center (MDACC) and 462 patients from The Cancer Genome Atlas (TCGA) to identify patterns of protein expression that drive tumorigenesis. A total of 163 validated proteins were analyzed by reverse phase protein array (RPPA). Unsupervised hierarchical clustering of the tumor proteins from the MDACC cohort was performed, and clustering was validated using RPPA data from TCGA CRC. Cox regression was used to identify predictors of tumor recurrence. Results. Clustering revealed dichotomization, with subtype A notable for a high epithelial-mesenchymal transition (EMT) protein signature, while subtype B was notable for high Akt/TSC/mTOR pathway components. Survival data were only available for the MDACC cohort and were used to evaluate prognostic relevance of these protein signatures. Group B demonstrated worse relapse-free survival (hazard ratio 2.11, 95% confidence interval 1.04-4.27, p = 0.039), although there was no difference in known genomic drivers between the two proteomic groups. Proteomic grouping and stage were significant predictors of recurrence on multivariate analysis. Eight proteins were found to be significant predictors of tumor recurrence on multivariate analysis: Collagen VI, FOXO3a, INPP4B, LcK, phospho-PEA15, phospho-PRAS40, Rad51, phospho-S6. Conclusion. CRC can be classified into distinct subtypes by proteomic features independent of common oncogenic driver mutations. Proteomic analysis has identified key biomarkers with prognostic importance, however these findings require further validation in an independent cohort.
Colorectal cancer (CRC) remains a leading cause of cancer death in the US, largely due to high tumor heterogeneity and inherent or acquired resistance to therapies. Efforts to classify CRC independent of TNM staging are largely gene expression based, however they have only provided limited differentiation in prognosis and treatment response in early-stage CRC. Protein expression and phosphorylation accurately reflects cellular function and tumor biology, and may provide unique and meaningful differences as we strive to define CRC taxonomy.
The Cancer Genome Atlas (TCGA) project interrogated CRC tumor biology by performing comprehensive molecular characterization of human colon and rectal cancers. This increased our knowledge of the genetic and epigenetic events involved in CRC pathophysiology, and, importantly, demonstrated that colon and rectal tumors are molecularly indistinguishable. 1 Zhang et al. 2 further investigated these genomic alterations by assessing tumor phenotype through proteomic analysis of 95 CRC tumor samples. Utilizing liquid chromatography-tandem mass spectrometry (LC-MS/MS), they identified discrete proteomic CRC subtypes and driver pathways critical in CRC tumorigenesis. However, little is known about the prognostic relevance of these proteins and protein signatures. To that end, we analyzed the functional proteome using reverse phase protein array (RPPA) in a large cohort of patients with CRC in the TCGA and a second cohort treated at the University of Texas MD Anderson Cancer Center (MDACC). We sought to determine if CRC tumor subtypes could be identified based on unique protein signatures, and investigate the prognostic implications of these functional proteomes.
MATERIALS AND METHODS

Collection of Tumor Protein Lysates and Reverse Phase Protein Array
Primary tumor tissue from 263 MDACC-archived CRC specimens with C30% malignant cells were macrodissected, and cellular proteins collected and denatured by 1% sodium dodecyl sulfate (SDS) with b-mercaptoethanol. Protein lysates were diluted in five twofold serial dilutions, and serial diluted lysates arrayed on nitrocellulose-coated slides (Grace Bio-labs, Bend, OR, USA) by Aushon 2470 Arrayer (Aushon BioSystems, Billerica, MA, USA). A total of 5808 array spots were arranged on each slide, with positive and negative controls, mixed cell lysates and dilution buffer. Slides were probed with validated primary antibodies plus a biotin-conjugated secondary antibody. Only antibodies with a Pearson correlation coefficient between RPPA and Western blotting of [0.7 were used in RPPA. Antibodies with a single or dominant band on Western blotting were further assessed by direct comparison with RPPA using cell lines with differential protein expression or modulated with ligands/inhibitors or small-interfering RNA (siRNA) for phospho-or structural proteins, respectively. The signal obtained was amplified using a DakoCytomation-catalyzed system (Dako, Carpinteria, CA, USA) and visualized by 3,3'-diaminobenzidine (DAB) colorimetric reaction. Slides were scanned, analyzed, and quantified using customized software-Array-Pro Analyzer software (MediaCybernetics, Rockville, MD, USA)-to generate spot intensity. Dilution curves were fitted with a logistic model (http://bioinformatics.mdanderson.org/OOMPA), which fits a single curve using all the dilution series on a slide, with signal intensity as the response variable and dilution steps as the independent variable. The fitted curve is plotted with the signal intensities, both observed and fitted, on the y-axis, and the log 2 concentration of proteins on the x-axis. Protein concentrations were normalized by median polish, corrected across samples by linear expression values using the median expression of all antibody experiments to calculate a loading correction factor for each sample.
Independently, RPPA data from 462 primary tumor tissues in the TCGA-archived colorectal tumor bank were also analyzed. Specimens were prepared using the technique described above and run on the same RPPA platform. This cohort was used for validation.
Unsupervised Hierarchical Clustering
RPPA was performed to determine protein levels of 163 phospho-and total proteins in the MDACC cohort and 171 phospho-and total proteins in the TCGA cohort. There were 127 proteins common to both the MDACC and TCGA cohorts. The median centered levels of the common proteins were used to perform hierarchical clustering of genes and patients via centroid linkage using GeneCluster 3.0 (http:// bonsai.hgc.jp/*mdehoon/software/cluster/software.htm). Clustering was performed independently in the MDACC and TCGA cohorts. LIMMA linear regression analysis was performed to determine the top discriminating proteins between the clusters in each cohort.
Statistical Analysis
Baseline characteristics were determined for each cluster in the MDACC and TCGA cohorts. To identify independent prognostic proteins, protein expression values were median centered. Cox regression was used for univariate analysis with bootstrap validation. A beta-uniform mixture (BUM) model 3 was used to calculate false discovery rates (FDRs) to correct for multiple comparisons. Genes with a p-value B0.028 were considered significant, with a specified FDR of 0.3. Multivariate analysis was performed using significant protein, clinical, and pathologic variables.
RESULTS
Unsupervised Hierarchical Clustering
Unsupervised clustering resulted in dichotomization of patients into distinct groups, subtypes A and B, each with similar patterns of protein expression between both cohorts (Fig. 1) . The top 40 significant proteins independently identified for both the MDACC and TCGA cohorts are listed in electronic supplementary Table 1 . Of these, 24 proteins were common to both. Subtype A accounted for 57% (150/ 263) and 60.6% (280/462) of tumors in the MDACC and TCGA cohorts, respectively. Subtype A was notable for increased levels of fibronectin, vascular marker CD31, and decreased levels of E-cadherin, indicative of epithelialmesenchymal transition (EMT) or reactive stroma. Conversely, subtype B demonstrated increased levels of phosphorylated AMP kinase T172, phospho-mTOR, and phosphorylated acetyl-coA carboxylase (ACC) S79, indicating deranged energy sensing and metabolic regulation. Phosphorylated AMP kinase is associated with phosphorylation of the tuberous sclerosis complex and decreased mTOR activation, suggesting that uncoupling of phospho-AMPK and phospho-mTOR in these tumors may facilitate ongoing tumor growth despite AMPK phosphorylation. Subtype B also exhibited increased total and phospho levels of receptor tyrosine kinases, including HER2, HER3, and BRAF, and demonstrated increased phospho-CRAF S338 and phospho-EGFR Y1173. These findings suggest that increased signaling through the receptor tyrosine kinase pathways may facilitate the upregulation of phospho-mTOR despite an increase in activated AMP kinase.
Baseline characteristics of patients in subtypes A and B are listed in Table 1 Similarly, TCGA cohort subtype A had more stage II disease (42.0% vs. 34.5%) and less stage IV (12.7% vs. 16.4%), although this did not reach significance. Subtype A trended toward a higher proportion of right-sided tumors (46.5% vs. 39.0%, p = 0.11). As seen in the MDACC cohort, subtype A also had less LVI (39.6% vs. 51.5%, p = 0.017) and higher BRAF mutations (15.5% vs. 0.6%, p = 0.002). Unlike the MDACC cohort, subtype A had a lower rate of KRAS mutations (38.8% vs. 49.7%, p = 0.029). Notably, a higher rate of KRAS mutations was seen in TCGA cohort overall (43.1% vs. 37.5%). The MDACC cohort only tested for mutations in codons 12 and 13, which may explain the lower mutation incidence. The proportion of patients with microsatellite instability (MSI) tested in the TCGA was only 18% (83/462), therefore the distribution of MSI tumors between subtypes could not be accurately validated. (Fig. 2) . Stage at diagnosis was also a predictor of RFS, with stage III disease conferring an HR of 3.12 (95% CI 1.38-7.09, p = 0.007), while age, BRAF mutation, and LVI were not significant. On multivariate analysis for OS, age (HR 1.08, 95% CI 1.05-1.12, p \ 0.001) and stage at diagnosis (HR 2.66, 95% CI 1.21-5.86, p = 0.015) were significant predictors of survival, but proteomic grouping was not (Table 2 ).
Prognostic Implications of Individual Proteins
Fourteen proteins were significant (p B 0.05) independent predictors of recurrence on univariate analysis after bootstrap validation. These proteins were notable for components of the energy balance/mTOR signaling pathway, including AMPK, mTOR, FOXO3a. Using an FDR of 0.3, nine proteins remained significant, with a p-value B0.028. On multivariate analysis, inclusive of known prognostic clinical and pathology variables, node-positive disease, Collagen VI, FOXO3a, INPP4B, LcK, phospho-PEA15 (Ser116), phospho-PRAS40, Rad51, and phospho-S6 (Ser240-244) remained significant prognostic factors for tumor recurrence (Table 3 ). Outcome data in TCGA cohort were limited, therefore we were unable to validate the proteomic subtype or individual protein prognostic relevance seen in the MDACC cohort.
DISCUSSION
Tumorigenesis results when somatic and/or acquired genetic and epigenetic alterations result in dysregulation of oncogenic signaling pathways affecting subsequent transcriptional activity. Efforts to successfully characterize these aberrant signaling pathways in CRC through genomic-or mRNA-based approaches have largely been limited by their imprecision in predicting tumor protein expression. [4] [5] [6] For this reason, direct evaluation of the functional proteome provides us with the opportunity to evaluate tumor phenotype and link it directly to the expanding knowledge of tumor genomics.
TCGA has successfully performed proteogenomic analysis across several cancer types, and identified tumor subtypes that cluster based on protein expression. 7 In doing so, they identified key pancancer pathways and potentially 2 Here we present our study of proteomic analysis using RPPA in a larger cohort of 263 colorectal patients treated at the MDACC with longterm follow-up and an emphasis on evaluating the prognostic implications of the CRC functional proteome.
Clustering analysis of 127 proteins from 263 CRC samples in the MDACC cohort demonstrated dichotomization into proteomic subtype A, characterized by high expression of proteins indicative of EMT/reactive stroma, and subtype B, characterized by high expression of RTK proteins. When RPPA data from 462 colorectal tumors in the TCGA study were subjected to the same unsupervised hierarchical clustering, these tumors also dichotomized into subtypes A and B with similar protein signatures. BRAF mutation was the only genetic driver found to be associated with a proteomic subtype, with BRAF mutant tumors clustering to proteomic subtype A in both cohorts. These data demonstrate that CRC can reliably and reproducibly be subtyped by unique protein signatures that appear to be independent of known oncogenic drivers. The ability to validate the protein signatures and subtypes seen in our study population with the TCGA data further strengthens our findings. Although the two proteomic subtypes likely represent an oversimplification of the diversity in protein expression patterns in CRC, this dichotomous split allows for early comparisons to start to tease out biologically significant differences.
Our study also uniquely demonstrates the prognostic relevance of the functional proteome. Unfortunately, these findings could not be validated in the TCGA cohort owning to a lack of outcome data. In the MDACC cohort, our data revealed that in patients with stage II/ III CRC, proteomic clustering predicts tumor recurrence, with proteomic subtype A demonstrating superior RFS when compared with subtype B. This improved RFS is observed despite higher expression of an EMT-like signature. TCGA also reported similar findings in their multi-omic evaluation of CRC, where CRC Cluster V, found to be enriched for reactive stroma and EMT signatures, similarly demonstrated superior outcomes when compared with the remaining CRC clusters. 7 They hypothesized that this improvement in outcomes in Cluster V was due to depleted TP53, APC, and KRAS mutations. We are not able to confirm or refute this hypothesis with our current hotspot mutation data.
Additionally, we identified individual proteins with prognostic implications. Our analysis revealed eight protein-independent predictors of RFS in stage II/ III CRC, more than were identified in TCGA study. 8 High expression of two proteins, FOX03 and INPP4B, was associated with poor RFS (HR 2.27, 95% CI 1.15-4.48, p = 0.018; and HR 3.03, 95% CI 1.15-4.48, p = 0.018, respectively). FOX03, a transcription factor that plays an important role in cell cycle modulation and apoptosis, may play a role in the TCGA-reported CRC Cluster VI, a high EMT, cell cycle, apoptotic cluster. INPP4B is a potent suppressor of AKT signaling (Fig. 3) , and while it was not implicated in CRC in the TCGA study, it is associated with hyperactive PI3K signaling and HER2 overexpression in breast cancer, possibly conferring more aggressive disease. 9 The remaining six proteins were positive prognostic markers for RFS. Collagen VI, a stromal component, has been widely studied, however its role in tumor biology is still controversial. It has been found to promote tumor progression, mitigating its effect through direct activation of the Akt-GSK-3b-b-catenin-TCF/LEF pathway in malignant cells, resulting in increased angiogenic and transcription factors. 10 However, in the TCGA study, Collagen VI is well represented in Cluster V, notable for a reactive/EMT signature and better RFS when compared with other clusters. 7 Additionally, Dennison et al. recently identified a similarly reactive subtype of breast cancer by Phospho-PEA15, phospho-PRAS40, and phospho-S6 are critical regulators of the energy/Akt/mTOR signaling pathway and are implicated in Clusters I and IV in the TCGA paper. In our study, all three were prognostic for longer RFS and may represent a potentially targetable pathway. Lck tyrosine kinase plays a major role in T-cell receptor signaling, and expression correlates closely with tumor-infiltrating lymphocyte volume. 12 The role of the immune system in CRC tumorigenesis is increasingly appreciated and immunotherapy therapies have demonstrated promise in subsets of CRC. Studies have shown a protective role of tumor inflammatory infiltrates in CRC. 13, 14 In our study, high levels of Lck expression were also a positive prognostic marker (HR 0.30, 95% CI 0.14-0.61, p = 0.001).
Rad51 is a key mediator of DNA repair and is critical for cellular response to DNA damage. Tennstedt et al. demonstrated a strong association between MSI high (MSI-H) CRC and RAD51 overexpression, consistent with what is known about mismatch repair deficiencies. 15 Despite this finding in the same study, there was a negative prognosis associated with RAD51 expression, discordant with the widely accepted good prognosis of MSI-H CRC. Our data confirm a weak association between MSI-H and RAD51 overexpression (r = 0.21), and reiterates that both are biomarkers for good prognosis.
CONCLUSIONS
Functional proteomic analysis can be used to reliably and reproducibly classify CRC into subtypes based on clustering proteomic features that reflect distinct differences in cellular signaling. These differences appear to be independent of the common oncogenic driver mutations that have been previously described. Additionally, we have identified key proteomic markers with prognostic importance independent of known clinical/pathological variables. These protein signatures may enhance our understanding of colorectal tumorigenesis and represent potential novel therapeutic targets. Further study is needed to validate these prognostic findings in an independent cohort. 
